<DOC>
	<DOCNO>NCT02428751</DOCNO>
	<brief_summary>The combination rituximab , cyclophosphamide , doxorubicin , vincristine , prednisone ( R-CHOP regimen ) first-line chemotherapy elderly patient diffuse large B-cell lymphoma ( DLBCL ) . The treatment-related toxicity , especially severe cardiac toxicity induce anthracycline drug ( doxorubicin ) , become major concern among elderly patient . Pegylated liposomal doxorubicin formulation doxorubicin prolong circulation time unique toxicity profile . Previous single arm study elderly patient lymphoma use pegylated liposomal doxorubicin instead traditional doxorubicin combination rituximab , cyclophosphamide , vincristine , prednisone ( novel R-CDOP regimen ) , demonstrate good safety profile , include less bone marrow suppression less cardiac toxicity , maintain efficacy . However , efficacy safety two regimen ( R-CHOP R-CDOP ) head-to-head compare randomize study . The aim study compare efficacy safety R-CDOP ( rituximab , cyclophosphamide , pegylated liposomal doxorubicin , vincristine , prednisone ) R-CHOP ( rituximab , cyclophosphamide , doxorubicin , vincristine , prednisone ) previously untreated elderly patient DLBCL .</brief_summary>
	<brief_title>R-CHOP Versus R-CDOP First-line Treatment Elderly Patients With Diffuse Large-B-cell Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>Pathologically confirm diagnosis CD20positive diffuse large Bcell lymphoma 60~80 year old Ann Arbor stage I~IV ECOG physical score 0~2 Have receive previous treatment lymphoma , include chemotherapy , radiotherapy , biotherapy Have least one clinically measurable lesion : &gt; = 2cm physical examination , &gt; = 1.5cm compute tomography ( CT ) magnetic resonance ( MR ) Life expectancy &gt; = 3 month Serum glutamic oxaloacetic transaminase ( SGOT ) serum glutamate pyruvate transaminase total bilirubin &lt; = 2 × upper limit normal ( ULN ) Glomerular filtration rate ( MDRD method ) &gt; = 30ml/min No abnormality blood coagulative function Generally normal bone marrow function : blood cell &gt; = 3,000/μL , absolute neutrophil count &gt; = 1,500/μL , hemoglobin &gt; = 100g/L , platelet &gt; = 75,000/μL No evidence active hepatitis B C virus , human immunodeficiency virus infection Left ventricular ejection fraction ( LVEF ) &gt; = 45 % measure two dimensional echocardiography multigated acquisition ( MUGA ) scan Cardiac function class III New York Heart Association ( NYHA ) classification Patients indolent lymphoma Positive result situ hybridization EpsteinBarr virus encode RNA ( EBER ) Serum EpsteinBarr virus DNA &gt; = 1,000 copies/ml Doublehit lymphoma confirm fluorescence situ hybridization ( FISH ) Primary mediastinal Bcell lymphoma Involvement central nervous system Bulky disease ( &gt; = 10cm ) History cardiac disease , include clinically significant ventricular tachycardia , atrial fibrillation , conduction block , myocardial infarction within 1 year , congestive heart failure , symptomatic coronary heart disease need medication Known allergic reaction component agent use chemotherapeutic regimen use study Previous exposure anthracycline drug , rituximab , chemotherapy lymphoma History malignant carcinoma within 5 year ( except carcinoma situ skin uterine cervix , prostatic carcinoma ) Currently enrol clinical study Other condition investigator consider inappropriate enrolling study</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Lymphoma , Large B-Cell , Diffuse</keyword>
	<keyword>liposomal doxorubicin</keyword>
	<keyword>doxorubicin</keyword>
	<keyword>event-free survival</keyword>
</DOC>